Better Health, an iPhone App Away: Sanofi SA (ADR) (SNY), Johnson & Johnson (JNJ)

Page 1 of 2

An Apple a day might not keep the doctor away, but the company’s AppStore carries several solutions for tracking health care on the go — and pharmaceutical companies continue to line up as backers.

Johnson & Johnson (NYSE:JNJ)

VIVUS, Inc. (NASDAQ:VVUS) has a newly released weight loss app that can be used by anyone, but the company’s obviously aiming at potential customers for its obesity drug Qsymia. The Q and Me app allows for the tracking of exercise and diet, while providing access to recipes and metrics readouts.

The VIVUS app has a lot of competition from long-standing nutrition sites like MyFitnessPal. But Q and Me becomes the latest in a growing trend of mobile solutions backed by pharmaceutical companies.

iBGStar Diabetes Manager (Sanofi)
Sanofi SA (ADR) (NYSE:SNY) supplements its multibillion-dollar insulin Lantus with a smartphone-enabled blood glucose monitor. The small iBGStar monitor can function on its own or connect to an Apple iPhone or iPad for tracking.

The accompanying app allows users to track meals, exercise, and glucose levels — all important factors in diabetes management. Blood sugar tracked over time can provide metrics showing the cause and effect of certain activities, such as jogging or eating a doughnut.

iChemoDiary (Merck & Co., Inc.)
Merck & Co., Inc. (NYSE:MRK)‘s  iChemoDiary app helps patients track chemotherapy treatments and record notes. The app also provides information about different drugs and their potential side effects. Patients can easily share the information with health care providers to identify any potential problems with the current regimen.

Cancer treatments tend toward intense personalization, both in the treatments used and the side effects suffered. This app could vastly streamline the process for both patient and doctor.

The free app is available through Apple’s iTunes and for desktop use. It’s branded through Merck’s medication Emend, which treats chemo-related nausea.

Psoriasis App (Johnson & Johnson)
Johnson & Johnson (NYSE:JNJ) subsidiary Janssen backs a Psoriasis App that includes functions for both health care providers and patients. The company’s psoriasis drug Stelara reached blockbuster status last year.

Page 1 of 2

Dividend Stock Alert - Billionaire Robbins' Top Dividend Idea With 70% Upside Potential

Get Paid 3.5% Per Year While Waiting For The Stock Appreciate 70%

Larry Robbins' Glenview Capital Opportunity Fund returned 101.7% in 2013 and Robbins personally made $750 million. The same fund returned 25.3% in 2014. In this FREE REPORT we will share Robbins' top dividend idea that yields 3.5% and has been increasing its dividends for 39 consecutive years. Robbins thinks the stock has the potential to appreciate 70%.

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click Here to Read Comments
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!